Tehran University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share By
Anti-Mullerian Hormone Predictive Levels to Determine the Likelihood of Ovarian Hyper-Response in Infertile Women With Polycystic Ovarian Morphology Publisher



Sene AA1 ; Ashrafi M1 ; Alaghmandfard N2 ; Mohammadi N3 ; Alisaraie MM4 ; Alizadeh A5
Authors

Source: International Journal of Fertility and Sterility Published:2021


Abstract

Background: The objective of this study was to investigate serum levels of anti-Mullerian hormone (AMH) in normal-ovulatory infertile women with polycystic ovarian morphology (PCOM) and their association with ovarian hyper-response. Materials and Methods: This prospective cohort study was carried out on 100 infertile women with PCOM who were treated with an antagonist/agonist triggered stimulation protocol at Shahid Akbar-Abadi Hospital IVF Centre, Tehran, Iran. Serum AMH levels were measured before starting the assisted reproductive technology (ART) cycle and the ovarian hyper-response was evaluated by retrieved oocyte numbers, ooestradiol levels on the triggering day, and the incidence of ovarian hyper-stimulation syndrome (OHSS) clinical signs and symptoms. Logistic regression and the area under the curve (AUC) were used to estimate the effects of AMH and the accuracy of the test. Results: Receiver operating characteristic (ROC) curve analysis showed that AMH could significantly predict ovarian hyper-response in PCOM patients (AUC=0.73). The estimated threshold value was 4.95 ng/ml, with a specificity of 74.58% (95% confidence interval [CI]: 50.85, 93.22) and sensitivity of 73.17% (95% CI: 48.78, 92.68). Logistic regression results showed a significant interaction between AMH and body mass index (BMI, P=0.008), which indi-cated that BMI had a moderation effect. Conclusion: Individualized stimulation protocols for patients with isolated PCOM and AMH greater than 4.95 ng/ml may significantly reduce the chances of developing OHSS. However, the AMH cut-off values to predict ovarian hyper-response differ for different BMI categories among PCOM patients; thus, it becomes a more precise predictive marker with increasing BMI. © 2021, Royan Institute (ACECR). All rights reserved.
Related Docs
View other Related Docs
1. Optimal Cutoff Value of Basal Anti-Mullerian Hormone in Iranian Infertile Women for Prediction of Ovarian Hyper-Stimulation Syndrome and Poor Response to Stimulation Female Fertility, Reproductive Health (2015)
2. Systematic Review of the Association Between Bmi and Antimullerian Hormone (Amh) Levels in Reproductive Aged Women, Iranian Journal of Endocrinology and Metabolism (2018)
3. Is Ovarian Reserve Associated With Body Mass Index and Obesity in Reproductive Aged Women? a Meta-Analysis, Menopause (2018)
Experts (# of related papers)
View all Related Experts
Ashraf Moini (6)
Ladan Kashani (3)
Other Related Docs
4. Age-Specific Reference Values and Cut-Off Points for Anti-Mullerian Hormone in Infertile Women Following a Long Agonist Treatment Protocol for Ivf, Journal of Endocrinological Investigation (2018)
5. Do Trends of Adiposity and Metabolic Parameters Vary in Women With Different Ovarian Reserve Status? a Population-Based Cohort Study, Menopause (2020)
6. Association Between Parity and Ovarian Reserve in Reproductive Age Women, European Journal of Obstetrics and Gynecology and Reproductive Biology (2016)
7. The Association of Amh Level With the Number and Quality of Oocytes in Women Undergoing Ivf/Icsi: A Single-Center Study, Journal of Reproduction and Infertility (2024)
8. Age Related Endocrine Patterns Observed in Polycystic Ovary Syndrome Patients Vs. Ovulatory Controls: Descriptive Data From a University Based Infertility Center, Archives of Endocrinology and Metabolism (2016)
9. Assisted Reproductive Outcomes in Women With Different Polycystic Ovary Syndrome Phenotypes: The Predictive Value of Anti-Mullerian Hormone, Reproductive BioMedicine Online (2016)
10. A Comparison of Fertility Rates in Women Undergoing Ivf With a Tubal Factor With Surgery, Tubal Factor Infertility Without Surgery, and Unexplained Infertility, Journal of Obstetrics# Gynecology and Cancer Research (2020)
11. Comparison of Serum Levels of Amh and Fsh Before and After Unilateral and Bilateral Laparoscopic Ovarian Drilling in Pcos Women Referred to Yas Infertility Clinic, Journal of Obstetrics# Gynecology and Cancer Research (2020)
12. Assessment the Health-Related Quality of Life in Women With Polycystic Ovary Syndrome, Tehran University Medical Journal (2020)
13. Letrozole As Co-Treatment Agent in Ovarian Stimulation Antagonist Protocol in Poor Responders: A Double-Blind Randomized Clinical Trial, International Journal of Reproductive BioMedicine (2019)
14. Serum Prostate-Specific Antigen Level in Women With Polycystic Ovary Syndrome: A Systematic Review and Meta-Analysis, Hormone and Metabolic Research (2019)
15. Early Administration of Gonadotropin-Releasing Hormone Antagonist Versus Flexible Antagonist Ovarian Stimulation Protocol in Poor Responders: A Randomized Clinical Trial, Middle East Fertility Society Journal (2021)
16. Relation of Follicular Fluid Soluble Receptor for Advanced Glycation End-Products Concentration and Anti Mullerian Hormone in Polycystic Ovary Syndrome and Non-Pcos Women Referring to in Vitro Fertilization Center: Case-Control Study, International Journal of Fertility and Sterility (2025)
17. Ovarian Volume, Not Follicle Count, Is Independently Associated With Androgens in Patients With Polycystic Ovary Syndrome, BMC Endocrine Disorders (2022)
18. Analysis of Ovarian Reserve Markers (Amh, Fsh, Afc) in Different Age Strata in Ivf/Icsi Patients, International Journal of Reproductive BioMedicine (2016)
19. Oocyte Quality and in Vitro Fertilization Outcome in Triggering With Gnrh Agonist Versus Hcg, Gazzetta Medica Italiana Archivio per le Scienze Mediche (2023)
20. The Effect of Letrozole Versus Artificial Hormonal Endometrial Preparation on Pregnancy Outcome After Frozen-Thawed Embryos Transfer Cycles: A Randomized Clinical Trial, Reproductive Biology and Endocrinology (2020)